Add Yahoo as a preferred source to see more of our stories on Google. BioInvent's monoclonal antibody has demonstrated an ORR of 24% when combined with MSD's Keytruda during a Phase IIa study in ...
Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining ...
Hosted on MSN
BioInvent posts strong interim data for BI‑1808 and KEYTRUDA combo in recurrent ovarian cancer
BioInvent International AB ( (SE:BINV)) has issued an update. BioInvent International has reported encouraging interim Phase 2a data for its first‑in‑class anti‑TNFR2 antibody BI‑1808 in combination ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Here are the new vendors that ...
LUND, SE / ACCESS Newswire / January 5, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first ...
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab), Merck & Co. Inc.’s reigning blockbuster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback